How should I taper off imipramine?

How to Taper Off Imipramine

Imipramine should be tapered gradually rather than stopped abruptly, with dose reductions of approximately 25% of the current dose every 1-2 weeks, extending to slower reductions (10-25 mg decrements every 2-4 weeks) as you approach lower doses, with the entire taper potentially taking several months to minimize withdrawal symptoms and prevent relapse. 1

FDA-Approved Tapering Guidance

The FDA label explicitly states that "dosage should be tapered off gradually rather than abruptly discontinued" to reduce the tendency to relapse 1. This is the foundational principle for all imipramine discontinuation.

• For patients on maintenance doses (50-150 mg/day for depression), begin tapering from the current maintenance dose 1
• The label emphasizes gradual reduction but does not specify exact taper schedules, leaving room for clinical judgment based on individual tolerance 1

Evidence-Based Tapering Protocol

Initial Phase (Higher Doses)

• Reduce by 25% of the current dose every 1-2 weeks when starting from therapeutic doses (100-200 mg/day) 1, 2
• For example: 150 mg → 112.5 mg → 84 mg → 63 mg, with each step lasting 1-2 weeks
• Monitor closely for withdrawal symptoms at each reduction 1

Middle Phase (Moderate Doses: 50-100 mg)

• Slow to 10-25 mg reductions every 2-4 weeks as you approach lower doses 1
• This mirrors principles from other antidepressant tapering where smaller absolute reductions become critical at lower doses 3, 4
• Example: 75 mg → 50 mg (wait 2-4 weeks) → 37.5 mg (wait 2-4 weeks) → 25 mg

Final Phase (Low Doses: <50 mg)

• Use the smallest possible dose decrements (12.5 mg or less) with intervals of 2-4 weeks between reductions 1, 2
• Consider extending intervals to monthly reductions if withdrawal symptoms emerge 5
• The final step from 12.5-25 mg to zero may require the longest interval (4-6 weeks) 2

Why Gradual Tapering Matters

Abrupt discontinuation or rapid tapering causes significant withdrawal symptoms in a substantial proportion of patients:

• Retrospective studies show that even with an average tapering period of 6.4 days, children experienced significant withdrawal symptoms across seven symptom categories 6
• Case reports document severe withdrawal syndromes (vomiting, digestive intolerance, dehydration) when tapering was too rapid 2
• Withdrawal symptoms from imipramine are less severe than with some other antidepressants (like alprazolam) but still clinically significant 7

Monitoring During Taper

Close supervision is required throughout the tapering process:

• Monitor for withdrawal symptoms including anxiety, insomnia, gastrointestinal distress (nausea, vomiting, diarrhea), headache, irritability, and mood changes 1, 2
• Watch for signs of depression relapse versus withdrawal symptoms—withdrawal typically has abrupt onset after dose reduction, while relapse develops more gradually 3
• Follow up at least monthly during active tapering, with more frequent contact (weekly or biweekly) during dose reductions 5
• Patients should be encouraged to report symptoms immediately, as they may signal the need to slow the taper further 1

Managing Withdrawal Symptoms

If moderate to severe withdrawal symptoms emerge:

• Pause the taper and maintain the current dose for 2-4 additional weeks until symptoms resolve 5
• Consider returning to the previous (higher) dose if symptoms are intolerable, then attempt a slower taper 2
• Extend intervals between reductions to 3-4 weeks or longer rather than making smaller dose decrements 8
• Provide symptomatic treatment for specific withdrawal symptoms (antiemetics for nausea, sleep aids for insomnia) 2

Critical Pitfalls to Avoid

Do NOT use alternate-day dosing as a tapering strategy:

• Extending the interval between doses (e.g., taking the same dose every other day) causes pronounced fluctuations in drug levels and receptor occupancy 9
• This approach dramatically increases withdrawal symptom risk and cannot be recommended 9
• Always reduce the daily dose while maintaining daily administration frequency

Do NOT rush the taper:

• Standard 2-4 week tapers provide minimal benefit over abrupt cessation for long-term users 3
• Patients on imipramine for ≥1 year may require tapers lasting several months 5
• The average 6.4-day taper used historically is far too rapid and causes significant withdrawal 6

Special Populations

Children (for enuresis treatment)

• The FDA recommends tapering gradually when discontinuing imipramine for enuresis 1
• Consider instituting a drug-free period after adequate therapeutic trial with favorable response 1
• Withdrawal symptoms may be more prevalent and intense in children than previously recognized 6
• Very progressive discontinuation is essential to avoid severe withdrawal syndromes 2

Elderly Patients

• Start at the lower end of dosing ranges and taper even more gradually 1
• Elderly patients may have decreased hepatic/renal function affecting drug clearance 1
• Monitor more frequently for both withdrawal symptoms and medication side effects 1

Maintenance vs. Discontinuation Decision

Before initiating a taper, establish whether discontinuation is appropriate:

• Half-dose maintenance (50% of acute treatment dose) prevents relapse in patients with panic disorder who responded well to acute treatment 10
• None of the patients on half-dose maintenance showed relapse during 12-month follow-up, contrasting with high relapse rates after full discontinuation 10
• For patients with recurrent depression or panic disorder, consider long-term maintenance at reduced doses rather than complete discontinuation 10

Timeline Expectations

Total taper duration should be:

• Minimum 8-12 weeks for patients on therapeutic doses for <1 year 4
• 4-6 months or longer for patients on long-term therapy (≥1 year) 5, 4
• Some patients may require tapers extending to 12 months, particularly those with prior withdrawal difficulties 5

Drug Interactions During Taper

Be aware that plasma imipramine levels can fluctuate if other medications are changed during tapering:

• CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, cimetidine) increase imipramine levels 1
• Hepatic enzyme inducers (barbiturates, phenytoin) decrease imipramine levels 1
• If adding or removing interacting medications during taper, adjust the tapering schedule accordingly and consider checking plasma levels 1